Antimicrobial drug interactions in the critically Ill patients

Current Clinical Pharmacology

Volumn 8, Issue 1, 2013, Pages 25-38

  Pereira, José M ^a   Paiva, José A ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Antibiotics; Antifungals; Antimicrobials; Critically ill; Drug drug interactions

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; COLCHICINE; CYCLOSPORIN; ERYTHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOMETACIN; METHOTREXATE; MIDAZOLAM; NORFLOXACIN; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TACROLIMUS; TELITHROMYCIN;

AREA UNDER THE CURVE; ARTICLE; CRITICALLY ILL PATIENT; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG INTERACTION; DRUG MONITORING; DRUG SAFETY; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL;

EID: 84873111844     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574884711308010005     Document Type: Article

References (170)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29(7): 1303-1310.
2. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34(2): 344-353.
3. Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 2006; 10(2): R42.
4. Esteban A, Frutos-Vivar F, Ferguson ND, et al. Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward. Crit Care Med 2007; 35(5): 1284-1289.
5. Vincent JL, Abraham E, Annane D, BernardG, Rivers E, Van den Berghe G. Reducing mortality in sepsis: new directions. Crit Care 2002; 6(suppl 3):S1-S18.
6. Vincent JL, Rello J, Marshall J, et al. EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302(21): 2323-2329.
7. Sierra P, Castillo J, Gómez M, Sorribes V, Monterde J, Castaño J. Potential and real drug interactions in critical care patients. Rev Esp Anestesiol Reanim 1997; 44(10): 383-387.
8. Nielsen EW, Dybwik K. Drug interactions in an intensive care unit. Tidsskr Nor Laegeforen 2004; 124(22): 2907-2908.
9. Meneses A, Monteiro HS. Prevalência de interações medicamentosas "droga-droga" potenciais em duas UTIs (pública X privada) de Fortaleza, Brasil. Rev Bras Ter Intensiva. 2000; 12(1): 4-7.
10. Jankel CA, Speedie SM. Detecting drug interactions: a review of the literature. DICP 1990; 24(10): 982-989.
11. Hartshorn EA. Drug interactions. Fam Community Health 1982; 5(2): 45-57.
12. Streetman DS. Metabolic basis of drug interactions in the intensive care unit. Crit Care Nurs Q 2000; 22(4): 1-13.
13. Rolan PE. Plasma protein binding displacement interactions: why are they still regarded as clinically important? Br J Clin Pharmacol 1994; 37(2): 125-128
14. Tatro DS. Drug interaction facts 2006: the authority on drug interactions. St. Louis (MO): Facts and Comparisons 2006.
15. Baxter K, Stockley IH. Stockley's drug interactions. 7th ed. London: Pharmaceutical Press 2005.
16. Neuhauser MM, Danziger LH. β-lactam antibiotics. In: Drug interactions in infectious diseases (2nd edition); Piscitelli SC, Rodvold KA, Ed. Totowa (NJ): Humana Press 2005: pp. 255-287.
17. Hansten PD, Horn JR. Hansten and Horn's Managing clinically important drug interactions 2005. St. Louis (MO): Facts and Comparisons 2005.
18. Wallace KL. Antibiotic-induced convulsions. Crit Care Clin 1997; 13(4):741-762.
19. Piscitelli SC, Rodvold KA. Drug interactions in infectious diseases. 2nd ed. Totowa (NJ): Humana Press; 2005.
20. Clause D, Decleire PY, Vanbinst R, Soyer A, Hantson P. Pharmacokinetic interaction between valproic acid and meropenem. Intensive Care Med 2005; 31(9):1293-1294.
21. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165(10):1095-1106.
22. Maglio D, Nicolau DP, Nightingale CH. Impact of pharmacodynamics on dosing of macrolides, azalides and ketolides. Infect Dis Clin North Am 2003; 17: 563-577
23. Pai MP, Graci D, Amsden GW. Macrolide drug interactions: an update. Ann Pharmacother 2000; 34(4): 495-513.
24. Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet 2005; 44(9): 915-934.
25. Petitjean O, Nicolas P, Tod M. Drug interactions during antiinfective treatments. In: Antimicrobial agents: antibacterials and antifungals. Bryskier A ed. Washington, DC: ASM Press 2005; pp. 1320-1352.
26. Pai MP, Momary KM, Rodvold KA. Antibiotic drug interactions. Med Clin Nort Am 2006; 90(6): 1223-1255.
27. Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an updated focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000; 50: 285-295.
28. Rengelshausen J, Goggelmann C, Burhenne J, et al. Contribution of increased oral bioavailability and reduced nonglomerular renal clear ance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol 2003; 56: 32-8.
29. Asakura E, Nakayama H, Sugie M, et al. Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol 2004; 484: 333-9.
30. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 1999; 59: 3944-8.
31. Wang L, Kitaichi K, Hui CS, et al. Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. Clin Exp Pharmacol Physiol 2000; 27: 587-93.
32. Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Evidence basis of a novel colchicine dose reduction algorithm to predict & prevent colchicine toxicity in the presence of P-gp/CYP P450 3A4 inhibitors. Arthritis Rheum 2011. doi: 10.1002/ art.30389.[Epub ahead of print]
33. Guay DRP. Quinolones. In: Drug interactions in infectious diseases (2nd edition); Piscitelli SC, Rodvold KA, Ed. Totowa (NJ): Humana Press 2005; pp. 215-254.
34. Avent CK, Krinsky D, Kirklin JK, et al. Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine. Am J Med 1988; 85: 452-3.
35. Elston RA, Taylor J. Possible interaction of ciprofloxacin with cyclosporin A. J Antimicrob Chemother 1988; 21: 679-80.
36. Rosado LJ, Siskind MS, Copeland JG. Acute interstitial nephritis in a cardiac transplant recipient receiving ciprofloxacin. J Thorac Cardiovasc Surg 1994; 107: 1364.
37. Borrás-Blasco J, Conesa-García V, Navarro-Ruiz A, Marín-Jiménez F, González-Delgado M, Gomez-Corrons A. Ciprofloxacin, but not levofloxacin, affects cyclosporine blood levels in a patient with pure red blood cell aplasia Am J Med Sci. 2005; 330(3): 144-6
38. Frederico S, Carrano R, Capone D, Gentile A, Palmiero G, Basile V. Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation. Clin Pharmacokinet 2006; 45: 169-175
39. Stass H, Delisen H, Kubitza D, Mai I, Bauer S, Roots I. Moxifloxacin does not alter ciclosporin pharmacokinetics in transplant patients in multiple-dose, uncontrolled, single centre study. Clin Drug Investig 2010; 30: 279-287.
40. Dalle JH, Auvrignon A, Vassal G, Leverger G. Interaction between methotrexate and ciprofloxacin. J Pediatr Hematol Oncol 2002; 24(4): 321-2.
41. Langlois C. Risk of seizures from the concomitant use of ciprofloxacin and phenytoin in patients with epilepsy. CMAJ 1998: 158: 104-5.
42. Susla GM. Miscellaneous antibiotics. In: Drug interactions in infectious diseases (2nd edition); Piscitelli SC, Rodvold KA, Ed. Totowa (NJ): Humana Press 2005; pp. 339-381.
43. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43(7): 1549-1555.
44. Rodvold KA, Erdman SM, Pryka RD. Vancomycin. In: Therapeutic drug monitoring. Schumacher GE, ed. Norwalk (CT): Appleton & Lange 1995; pp. 587-632.
45. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
46. Schriever CA, Fernández C, Rodvold KA, Danziger LH. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 2005; 62(11): 1145-1158.
47. Product information: Tygacil, tigecycline. Philadelphia: Wyeth Pharmaceuticals; 2005.
48. Bertino JS Jr, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993; 167(1): 173-179.
49. Butkus DE, de Torrente A, Terman DS. Renal failure following gentamicin in combination with clindamycin. Nephron 1976; 17(4): 307-313.
50. Penzak SR. Mechanisms of drug interactions II: transport proteins. In: Drug interactions in infectious diseases (2nd edition); Piscitelli SC, Rodvold KA, Ed. Totowa (NJ): Humana Press 2005: pp.41-82.
51. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42(9): 819-850.
52. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005; 39: 15-20.
53. Petrosillo N, Chinello P, Proietti MF, et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 2005; 11: 682-83
54. Ullmann AJ, Sanz MA, Tramarin A, et al. On behalf of the Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators. Prospective study of amphothericin B formulations in immunocompromised patients in 4 european countries. Clin Infect Dis 2006 43: e29-38.
55. Kaskel P, Tuschy S, Wagner A, et al. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. Ann Hematol 2008; 87: 311-319.
56. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-324.
57. Patel R. Antifungal agents: amphotericin B preparations and flucytosine. Mayo Clin Proc 1998; 73: 1205-1225.
58. Chung DK, Koenig MG. Reversible cardiac enlargement during treatment with amphotericin B and hydrocortisone. Am Rev Respir Dis 1971; 103: 831-841.
59. Gubbins PO, Amsden JR. Drug-drug interactions of antifungal agents and implications for patient care. Expert Opin Pharmacother 2005; 6: 2231-2243.
60. Gubbins PO. Mould active azoles: pharmacokinetics, drug interactions in neutropenic hosts. Curr Opin Infect Dis 2007; 20: 579-586.
61. Gubbins PO, McConnell SA, Amsden JR. Drug interactions associated with antifungal agents. In: Drug Interactions in Infectious Diseases, 2nd edition, Piscitelli SC, Rodvold KA eds., Totowa, NJ: Humana Press, 2005: 289-337.
62. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111-180.
63. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996; 82: 511-516.
64. Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998; 54: 53-58.
65. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol 1997; 51: 415-419.
66. Krishna G, Moton A, Ma L, et al. Effects of oral posaconazole on the pharmacokinetics of oral and intravenous midazoloam: a phase I randomized, open-label, crossover study in healthy volunteers. Clin Ther 2009; 31: 286-298.
67. Varhe A, OLkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56: 601-607.
68. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 2006; 79: 362-370.
69. Ahonen J, Olkkola KT, Neuvonen PJ. The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam Clin Pharmacol 1996; 10: 314-318.
70. Saari TI, Laine K, Bertilsson L, Neuvonen PJ, Olkkola KT. Voriconazole and fluconazole increase the exposure to oral diazepam. Eur J Clin Pharmacol 2007; 63: 941-949.
71. Ahonen J, Olkkola KT, Neuvonen PJ. Lack of effect of the antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. Ther Drug Monit 1996; 18: 124-127.
72. Oda M, Kotegawa T, Tsutsumi K, Ohtani Y, Kuwatani K, Nakano S. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur J Clin Pharmacol 2003; 59: 615-619.
73. Otsuji Y, Okuyama N, Aoshima T, Fukasawa T, Kato K, Gerstenberg G, Miura M, Ohkubo T,Sugawara K, Otani K. No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam. Ther Drug Monit 2002; 24: 375-378.
74. Leather H, Boyette RM, Tian L, Wingard JR. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2006; 12: 325-334.
75. Billaud EM, Guillemain R, Tacco F, Chevalier P. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol 1998; 46: 271-272.
76. Templeton IE, Thummel KE, Kharasch ED, et al. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 2008; 83: 77-85.
77. Romero AJ, Le Pogamp P, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant recipients. Clin Pharmacol Ther 2002; 71: 226-234.
78. Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002; 46: 3091-3093.
79. Tintillier M, Kirch L, Goffin E, Cuvelier C, Pochet JM. Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol Dial Transplant 2005; 20: 664-665.
80. Anonymous. Immunosuppressive drug interactions with antiinfective agents. Am J Transplant 2004; 4 (Suppl.10): 164-166.
81. Omar G, Whiting PH, Hawksworth GM, Humphrey MJ, Burke MD. Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. Ther Drug Monit 1997; 19: 436-445.
82. Mañez R, Martin M, Raman D, et al. Fluconazole therapy in transplant recipients receiving FK506. Transplantation 1994; 57: 1521-1523.
83. Krüger HU, Schuler U, Zimmermann R, Ehninger G. Absence of significant interaction of fluconazole with cyclosporin. J Antimicrob Chemother 1989; 24: 781-786.
84. Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991; 51: 1014-1018.
85. Lopez-Gil JA. Fluconazole-cyclosporine interaction: a dosedependent effect? Ann Pharmacother 1993; 27: 427-430.
86. Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant recipients. Transplantation 1996; 61: 1268-1272.
87. Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007; 27: 825-834.
88. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26: 1730-1744.
89. Varis T, Kaukonen KM, Kivistö KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 1998; 64: 363-368.
90. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001; 51: 443-450.
91. Varis T, Kivistö KT, Backman JT, Neuvonen PJ. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. Pharmacol Toxicol 1999; 85: 29-32.
92. Varis T, Kivistö KT, Backman JT, Neuvonen PJ. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenalsuppressant effect. Clin Pharmacol Ther 2000; 68: 487-494.
93. Varis T, Kivistö KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 2000; 56: 57-60.
94. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 54-61.
95. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-341.
96. Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64: 58-65.
97. Mazzu AL, Lasseter KC, Shamblin EC, Agarwal V, Lettieri J, Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000; 68: 391-400.
98. Kivistö KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 49-53.
99. Ishigam M, Uchiyama M, Kondo T, et al. Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and predictions of in vivo drug-drug interactions. Pharm Res 2001; 18: 622-631.
100. Kantola T, Backman JT, Niemi M, Kivistö KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000; 56: 225-229.
101. Shaukat A, Benekli M, Vladutiu GD, Slack JL, Wetzler M, Baer MR. Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 2003; 37: 1032-1035.
102. Hazin R, Abuzetun JY, Suker M, Porter J. Rhabdomyolysis induced by simvastatin-fluconazole combination. J Natl Med Assoc 2008; 100: 444-446.
103. Kahri J, Valkonen M, Bäcklund T, Vuoristo M, Kivistö KT. Rhabdomyolysis in a patient receiving atorvastatin and fluconazole. Eur J Clin Pharmacol 2005; 60: 905-907.
104. Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996; 24: 422-428.
105. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukemia. Br J Haematol 1997; 97: 663-665.
106. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-637.
107. Muijser RBR, Goa KL, Scott LJ. Voriconazole in the treatment of invasive aspergillosis. Drugs 2002; 18: 2655-2664.
108. Bonay M, Jonville-Bera AP, Diot P, Lemarie E, Lavandier M, Autret E. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf 1993; 9: 309-311.
109. Ducharme MP, Slaughter RL, Warbasse LH, et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 1995; 58: 617-624.
110. Jaruratanasirikul S, Sriwiriyajan S. Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. Eur J Clin Pharmacol 1998; 54: 155-158.
111. Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following coadministration to healthy men. Curr Med Res Opin 2007; 23: 545-552.
112. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003; 56(Suppl. 1): 37-44.
113. Blum RA, Wilton JH, Hilligoss DM, et al. Effect of fluconazole on disposition of phenytoin. Clin Pharmacol Ther 1991; 49: 420-425.
114. Krishna G, Sansone-Parsons A, Kantesaria B. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr Med Res Opin 2007; 23: 1415-1422.
115. Apseloff G, Hilligoss DM, Gardner MJ, et al. Induction of fluconazole metabolism by rifampin: in vivo study in humans. J Clin Pharmacol 1991; 31: 358-361.
116. Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997; 19: 609-613.
117. Burmúdez M, Fuster JL, Llinares E, Galera A, Gonzalez C. Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. J Pediatr Hematol Oncol 2005; 27: 389-392.
118. Bashir H, Motl S, Metzger ML, et al. Itraconazole enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma. J Pediatr Hematol Oncol 2006; 28: 33-35.
119. Porter CC, Carver AE, Albano EA. Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X. Pediatr Blood Cancer 2009; 52: 298-300.
120. Mantadakis E, Amoiridis G, Kondi A, Kalmanti M. Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia. J Pediatr Hematol Oncol 2007; 29: 130.
121. Eiden C, Palenzuela G, Hillaire-Buys D, et al. Posaconazoleincreased vincristine neurotoxicity in a child: a case report. J Pediatr Hematol Oncol 2009; 31: 292-295.
122. Lohinavy M, Lohitnavy O, Thangkeattiyanon O, Srichai W. Reduced oral itraconazole bioavailability by antacid suspension. J Clin Pharm Ther 2005; 30: 201-206.
123. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004; 48: 804-808.
124. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53: 958-966.
125. Lim SG, Sawyerr AM, Hudson M, Sercombe J, Pounder RE. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther 1993; 7: 317-321.
126. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003; 57: 218-222.
127. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006; 50: 1881-1883.
128. Mikus G, Schöwel V, Drzewinska M, et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006; 80: 126-135.
129. Liu P, Foster G, Gandelman K, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007; 51: 3617-3626.
130. Damle B, LaBadie R, Crownover P, Glue P. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol 2008; 65: 523-530.
131. Pereira JM, Paiva JA. Antifungal therapy in the ICU: the bug, the drug and the mug. In: Annual Update in Intensive Care andEmergency Medicine 2011; Vincent JL, Ed. Springer 2011: pp.516-530.
132. Nguyen TH, Hoppe-Tichy T, Geiss HK, et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 2007; 60: 100-106.
133. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cyclosporine A in patients with invasive fungal infections. Bone Marrow Transplant 2004; 34: 13-20.
134. Michele I, Villmann M. Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm 2006; 63: 1693-1703.
135. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445-1457.
136. Cappelletty D, Eiselstein-Mc K.K. The Echinocandins. Pharmacotherapy 2007; 27: 369-388.
137. Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60: 363-369.
138. Stone JA, Migoya EM, Hickey L, et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004; 48: 4306-4314.
139. Colburn DE, Giles FJ, Oladovich D, Smith JA. In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology 2004; 9: 217-221
140. Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005; 45: 227-233.
141. Pfizer. Ecalta_ Fachinformation. Karlsruhe: Pfizer, 2007.
142. Hebert MF, Townsend RW, Austin S, et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 954-960.
143. Garau J, Bouza E, Chastre J, Gudiol F, Harbarth S. Management of methicillin-resistant Staphylococcus aureus infections. Clin Microbiol Infect 2009; 15: 125-136.
144. Bayer AS, Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicilin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis 1985; 151: 157-165.
145. Levine DP, From BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicilin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674-680.
146. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: 2463-2467.
147. Falagas ME, Matthaiou DK, Bliziotis IA. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 2006; 57: 639-47.
148. Marcus R, Paul M, Elphick H, Leibovici L. Clinical implications of β-lactam-aminoglycoside synergism: systematic review of randomized trials. Int J Antimicrob Agents 2011; 37: 491-503.
149. Hubbard RB, Mathur RM, MacFarlane JT. Severe communityacquired legionella pneumonia: treatment, complications and outcome. Quarterly Journal of Medicine 1993; 86: 327-332.
150. Lepper MH, Dowling HP. Treatment of pneumococci meningitis with penicillin compared with penicillin plus aureomycin: studies including observations on an apparent antagonism between penicillin and aureomycin. Arch Intern Med 1951; 88(4):489-494.
151. Gutmann L, Williamson R, Kitzis MD, et al. Synergism and antagonism in double beta-lactam antibiotic combinations. Am J Med 1986; 80 (suppl 5C): 21-29.
152. Weisblum B. Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: The resistance phenotype, its biological diversity, and structural element that regulate expression--a review. J Antimicrob Chemother 1985; 16 (suppl A): 63-90.
153. Kiffer C, Sampaio J, Sinto S, et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis 2005; 52: 317-322.
154. Kiratisin P, Apisarnthanarak A, Kaewdaeng S. Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant. Int J Antimicrob Agents 2010; 36: 243-246.
155. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337: 15-21.
156. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
157. Louie A, Kaw P, Banerjee P, Liu W, Chen G, Miller MH. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis. Antimicrob Agents Chemother 2001; 45: 485-2212;94.
158. Candel FJ, Matesanz M, Mensa J. Sequential prescription of antifungals in invasive fungal infection: the importance of mechanism of action. Int J Antimicrob Agents 2008; 32 (Suppl 2): S133-S135.
159. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-2212;1228.
160. Kontoyiannis DP, Lewis RE, Sagar N, May G, Prince RA, Rolston KV. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy. Antimicrob Agents Chemother 2000; 44: 2915-8.
161. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA. Combination treatment of invasive fungal infections. Clin Microbiol Rev. 2005; 18:163-94.
162. Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003; 47: 106-17.
163. Ortoneda M, Capilla J, Javier Pastor F, Pujol I, Guarro J. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis 2004;48:69-71.
164. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Cin Infect Dis 2004; 39: 797-802.
165. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320-326.
166. Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer. 2003 Feb 15; 97:1025-1032.
167. Hossain MA, Reyes GH, Long LA, Mukherjee PK, Ghannoum MA. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J Antimicrob Chemother 2003; 51: 1427-1429.
168. Oliveira ER, Fothergill AW, Kirkpatrick WR, Coco BJ, Patterson TF, Redding SW. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata. Antimicrob Agents Chemother 2005; 49: 3544-3545.
169. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA. Combination treatment of invasive fungal infections. Clin Microbiol Rev. 2005; 18: 163-94.
170. Dannaoui E, Afeltra J, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother 2002; 46: 2708-2711.